-
1.发明公开
公开(公告)号：EP1242049A1
公开(公告)日：2002-09-25
申请号：EP00986510.6
申请日：2000-12-13
申请人： Epimmune Inc.
发明人： FIKES, John , SETTE, Alessandro , SIDNEY, John , SOUTHWOOD, Scott , CELIS, Esteban , KEOGH, Elissa , CHESNUT, Robert
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K45/06 , C07K14/4748 , C07K14/705 , C07K14/70539
摘要： A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100 % identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.
-
2.发明公开INDUCING CELLULAR IMMUNE RESPONSES TO PROSTATE CANCER ANTIGENS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS 审中-公开诱导细胞免疫应答抗前列腺癌抗原通过肽和核酸CONNECTIONS
公开(公告)号：EP1244465A1
公开(公告)日：2002-10-02
申请号：EP00989560.8
申请日：2000-12-20
申请人： Epimmune Inc.
发明人： FIKES, John , SETTE, Alessandro , SIDNEY, John , SOUTHWOOD, Scott , CHESNUT, Robert , CELIS, Esteban , KEOGH, Elissa
IPC分类号： A61K38/08 , A61K39/00 , A61K39/385 , A61K39/39 , C07H21/04 , C07K14/435
CPC分类号： C07K14/4748 , A61K39/00
-
3.发明公开INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS 审中-公开用肽和核酸组合物诱导HER2 / neu细胞免疫应答
公开(公告)号：EP1239866A1
公开(公告)日：2002-09-18
申请号：EP00984214.7
申请日：2000-12-11
申请人： Epimmune Inc.
发明人： FIKES, John , SETTE, Alessandro , SIDNEY, John , SOUTHWOOD, Scott , CHESNUT, Robert , CELIS, Esteban , KEOGH, Elissa
IPC分类号： A61K38/00 , A61K38/03 , A61K38/08 , A61K38/10 , A61K38/16 , C07K7/00 , C07K9/00 , C07K14/435 , C07H21/02 , C07H21/04
CPC分类号： A61K39/0011 , A61K39/00 , A61K2039/5154 , A61K2039/605 , C07K14/71
摘要： This invention uses our knoeledge of the mechanisms by which antigen is recognized by T cells to identify and prepare HER2/neu epitopes, and to develop epitope-based vaccines directed towards HERS2/neu-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
摘要翻译： 本发明使用我们对T细胞识别和制备HER2 / neu表位以及开发针对HERS2 / neu的肿瘤的基于表位的疫苗的机制的了解。 更具体地说，该应用传达了我们对药物组合物的发现和用于预防和治疗癌症的方法。
-
4.发明公开INDUCING CELLULAR IMMUNE RESPONSES TO CARCINOEMBRYONIC ANTIGEN USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS 审中-公开STIMULUSCULLÄRER免疫反应一个CARCINOEMBRYONEN抗原肽使用和核酸组合物
公开(公告)号：EP1235848A1
公开(公告)日：2002-09-04
申请号：EP00984204.8
申请日：2000-12-11
申请人： Epimmune Inc.
发明人： FIKES, John , SETTE, Alessandro , SIDNEY, John , SOUTHWOOD, Scott , CHESNUT, Robert , CELIS, Esteban , KEOGH, Elissa
IPC分类号： C07H21/04 , C07H21/02 , C07K4/12 , C07K7/00 , C07K9/00 , C07K14/705 , A61K38/04 , A61K38/08 , A61K38/10 , A61K38/17
CPC分类号： A61K39/0011 , A61K39/00 , A61K2039/5154 , A61K2039/605 , C07K14/70503
摘要： This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare carcino-embryonic antigen (CEA) epitopes, and to develop epitope-based vaccines directed towards CEA-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
-
公开(公告)号：EP1495322A2
公开(公告)日：2005-01-12
申请号：EP03718231.8
申请日：2003-04-07
申请人： Epimmune Inc.
CPC分类号： C07K14/70539 , C07K14/4748 , C07K14/70503
摘要： Heteroclitic analogs of class I epitopes are prepared by providing convervative, semi-conservative, or non-conservative amino acid substitutions at positions 3 and/or 4 and/or 5 and/or 6 and/or 7 and/or 8 and/or 9 and/or 10 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wild-type epitopes.
-
6.发明公开INDUCING CELLULAR IMMUNE RESPONSES TO P53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS 审中-公开诱导的细胞免疫应答P53以肽和核酸化合物
公开(公告)号：EP1237564A1
公开(公告)日：2002-09-11
申请号：EP00984231.1
申请日：2000-12-11
申请人： Epimmune, Inc.
发明人： FIKES, John , SETTE, Alessandro , SIDNEY, John , SOUTHWOOD, Scott , CHESNUT, Robert , CELIS, Esteban , KEOGH, Elissa
IPC分类号： A61K38/00 , A61K38/03 , A61K38/08 , A61K38/16 , A61K39/00 , C07H21/00 , C07K9/00 , C07K14/00
CPC分类号： C07K14/4746 , A61K39/00
摘要： This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare p53 epitopes, and to develop epitope-based vaccines directed towards p53-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
-
7.发明公开INDUCING CELLULAR IMMUNE RESPONSES TO MAGE2/3 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS 审中-公开诱导细胞免疫应答MAGE2 / 3使用的肽和核酸PREPARATIONS
公开(公告)号：EP1235841A1
公开(公告)日：2002-09-04
申请号：EP00984183.4
申请日：2000-12-11
申请人： Epimmune Inc.
发明人： FIKES, John , SETTE, Alessandro , SIDNEY, John , SOUTHWOOD, Scott , CHESNUT, Robert , CELIS, Esteban , KEOGH, Elissa
IPC分类号： C07H21/02 , C07H21/04 , C07H21/00 , A61K38/04 , A61K35/08 , A61K38/10 , A61K38/16 , A61K39/00 , A61K48/00 , C07K9/00 , C07K7/00 , C07K11/00
CPC分类号： C07K14/4748 , A61K39/0011 , A61K2039/5154 , A61K2039/53 , A61K2039/6031 , C07K2319/00
摘要： The invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare MAGE2/3 epitopes, and to develop epitope-based vaccines directed towards MAGE2/3-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.03 秒)
